India plans to set up a nearly Rs 1 lakh crore (US$ 1.3 billion) fund to provide boost to companies to manufacture pharmaceutical ingredients domestically. This move comes after supply chain was disrupted due to the coronavirus pandemic exposed the country’s dependence on China and raised the threat of drug shortages.
The program consists of spending on infrastructure for drug manufacturing centers and financial incentives of up to 20 per cent of incremental sales value over the next eight years, according to a government statement.
Currently, India imports almost 70 per cent of its active pharmaceutical ingredients, the chemicals that make a finished drug work, from China. Hubei province, the epicenter of the coronavirus outbreak has been major source of these ingredients. As the world’s single largest exporter of generic drugs, India is responsible for about 20 per cent of the world’s supply.
Source: IBEF
Image Courtesy: Pharmaceutical Technology
You may also like
-
Bharat Dynamics Expands Missile Manufacturing Network Across India
-
Kirloskar Oil Engines and DEUTZ Join Forces on Global 1.6-Litre Engine Platform
-
GRSE Partners DNV and Damen to Expand Advanced Shipbuilding and Indigenous Dredger Technology
-
Siliconia Expands Defence R&D After Landmark Indian Navy SPRINT Technology Contract
-
Cochin Shipyard Begins Construction of Four Advanced Battery-Electric Tugs for Svitzer
